N-acetyl-beta-D-glucosaminidase: A new approach to the screening of hypertensive patients for renal disease.
Urinary activity of the enzyme, N-acetyl-beta-D-glucosaminidase (N.A.G.) was examined as a screening test for renal disease in patients with hypertension. Renal disease was present in 64% of patients with increased N.A.G., compared with only 14% of patients with normal N.A.G. The measurement of N.A.G. is cheap and convenient and this simple test warrants further assessment in hypertension as a guide to the need for further investigation.
D000117:Acetylglucosamine; D000118:Acetylglucosaminidase / Q000652:urine; D000700:Analgesics / Q000009:adverse effects; D002908:Chronic Disease; D003951:Diagnostic Errors; D005921:Glomerulonephritis / Q000175:diagnosis; D006801:Humans; D006977:Hypertension, Renal / Q000175:diagnosis / Q000201:enzymology*; D007669:Kidney Calculi / Q000175:diagnosis; D007674:Kidney Diseases / Q000139:chemically induced / Q000175:diagnosis* / Q000201:enzymology; D052177:Kidney Diseases, Cystic / Q000175:diagnosis; D009404:Nephrotic Syndrome / Q000175:diagnosis
D000700:Analgesics; D000118:Acetylglucosaminidase; D000117:Acetylglucosamine